In September, I took a look, in a series of posts, at two companies that had crested the trillion dollar market cap mark, Apple Inc. (NASDAQ:AAPL) and......
(read more)December 4 - News, Stock Analysis, Tech - Comments
It seems like ancient history, but it was just 2001, when General Electric Company (NYSE:GE) was the most valuable company in the world, commanding a......
(read more)November 15 - News, Stock Analysis - Comments
Value stocks have been underperforming growth stocks and value investors have been hurting. According to Ken French’s calculations growth stocks......
(read more)June 8 - Hedge Fund Investor Letters, Hedge Funds, News, Stock Analysis - Comments
If you are building a portfolio, then you should consider adding insurance stocks, especially if you are looking for long-term returns. Of course, insurance......
(read more)May 29 - News, Stock Analysis - Comments
New York Times Co (NYSE:NYT) has enjoyed a strong bull run over the past 20 months, more than doubling in value since the beginning of October 2016, just......
(read more)May 26 - News, Stock Analysis - Comments
Spotify Technology (NYSE:SPOT) has been a hot topic as of late, and for good reason. The company went public early this month, making waves in the market......
(read more)May 4 - News, Stock Analysis, Tech - Comments
Fossil Group Inc (NASDAQ:FOSL) was one of the top performing stocks on the Nasdaq in the first quarter, jumping by 63.5%. Much of that love from the market......
(read more)April 3 - News, Stock Analysis, Tech - Comments
Financial stocks are on the cusp of a momentous year ahead. Barring the February 2018 market correction, banking and financial stocks are on the way up......
(read more)March 23 - Macroeconomic Predictions, News, Stock Analysis - Comments
Insider Monkey is in the business of identifying and following smart insiders, hedge fund managers and prominent investors. Our flagship investment strategy......
(read more)March 12 - Commodities, Hedge Fund Investor Letters, Hedge Funds, News, Stock Analysis - Comments
Netflix, Inc. (NASDAQ:NFLX) remains a major target of billionaire hedge fund manager David Einhorn of Greenlight Capital, who’s been launching verbal......
(read more)July 21 - Hedge Fund Investor Letters, Hedge Funds, News, Stock Analysis, Tech - Comments
Discover Financial Services (NYSE:DFS) doesn’t get no respect. That’s the message from Burr Capital LLC’s Rahul Ray, who discussed the......
(read more)July 12 - Hedge Fund Investor Letters, Hedge Funds, News, Stock Analysis - Comments
We published an article this morning providing a detailed breakdown of the Sohn Investment Conference presentation made by Social Capital CEO Chamath......
(read more)May 24 - Hedge Funds, News, Stock Analysis, Tech - Comments
Social Capital CEO Chamath Palihapitiya was one of the show-stoppers at the recent Sohn Investment Conference in New York, pitching a Tesla Inc (NASDAQ......
(read more)May 24 - Hedge Funds, News, Stock Analysis, Tech - Comments
International Game Technology Ordinary Shares (NYSE:IGT) scored a very favorable deal with the sale of its Double Down Interactive unit according to commentary......
(read more)May 11 - Hedge Fund Investor Letters, Hedge Funds, News, Stock Analysis, Tech - Comments
William Martin of Raging Capital Management believes TrueCar Inc (NASDAQ:TRUE) investors should pay attention to objects in their investment’s rear......
(read more)May 11 - Hedge Fund Investor Letters, Hedge Funds, News, Stock Analysis - Comments
Lions Gate Entertainment Corp. (USA) (NYSE:LGF) investors can probably point at least some of the blame for Lions Gate’s lackadaisical stock performance......
(read more)May 8 - Hedge Fund Investor Letters, Hedge Funds, News, Stock Analysis - Comments
Billionaire Dan Loeb, the head of $15 billion hedge fund Third Point, has his eyes set on a $20 billion prize. The money manager’s first-quarter......
(read more)May 6 - Activism, Hedge Fund Investor Letters, Hedge Funds, News, Stock Analysis - Comments
Warren Buffett of Berkshire Hathaway has been an investing machine for five decades, delivering stunning returns during that time. A mere $1,000 invested......
(read more)May 5 - Hedge Funds, Market Movers, News, Stock Analysis, Tech - Comments
David Einhorn, the billionaire manager of Greenlight Capital doesn’t exactly have a positive image of Tesla Inc (NASDAQ:TSLA) investors, viewing......
(read more)May 5 - Hedge Fund Investor Letters, Hedge Funds, News, Stock Analysis, Tech - Comments
Vilas Capital is probably no stranger to Tesla Inc (NASDAQ:TSLA) investors, as the fund has been an outspoken critic of Tesla in the past, calling it &#......
(read more)May 4 - Hedge Fund Investor Letters, Hedge Funds, News, Stock Analysis, Tech - Comments
Cliffs Natural Resources Inc. (NYSE:CLF) insiders have a history of buying up shares in clusters, the last cluster of which we saw in late-October/early......
(read more)May 4 - Commodities, Insider Trading, Market Movers, News, Stock Analysis - Comments
It’s been a tough run for Glenview Capital, the hedge fund run by billionaire Larry Robbins, which has endured two losing years in a row (an 18.......
(read more)May 3 - Hedge Funds, News, Stock Analysis - Comments
Last week, Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) announced data from a Phase II study of its lead development asset Anabasum. The data appeared......
(read more)April 4 - News, Stock Analysis - Comments
Introduction The threat of rising interest rates is all the rage in financial circles today. However, the seminal question is: How real is the threat,......
(read more)March 24 - News, Stock Analysis - Comments
The cannabis space has been one of the most closely watched, and the most active, sectors across the last twelve months. The Viridian Cannabis Stock Index......
(read more)March 22 - News, Stock Analysis - Comments
AstraZeneca PLC (ADR) (NYSE:AZN) has acknowledged the receipt of the Complete Response Letter (CRL) from the U.S. Food and Drug Administration for ZS......
(read more)March 21 - News, Stock Analysis - Comments
Nektar Therapeutics (NASDAQ:NKTR) is one of the week’s biggest winners in biotech so far, with the company soaring during the Monday session on the......
(read more)March 21 - News, Stock Analysis - Comments
In an effort to enhance collaboration with Circassia Pharmaceuticals, AstraZeneca PLC (ADR) (NYSE:AZN) has acquired an equity stake valued at $50 million......
(read more)March 20 - News, Stock Analysis - Comments
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has unveiled the authorized generic version of Minastrin, an oral contraceptive that is combined......
(read more)March 20 - News, Stock Analysis - Comments
At the end of last week, Amgen, Inc. (NASDAQ:AMGN) announced some data from its large-scale trial of its cardiovascular risk asset Repatha. The drug first......
(read more)March 20 - News, Stock Analysis - Comments
As you know, I review the list of dividend increases every single week as part of my monitoring process. I usually focus my attention on the ones that......
(read more)March 20 - Dividend Stocks, News, Retirement, Stock Analysis - Comments
Positive results for the Phase III study meant to test the experiences of patients using the eye insert known as Dextenza to relieve pain in a post-surgical......
(read more)March 17 - News, Stock Analysis - Comments
Plans to start a new Phase II study of SER-109, branded ECOSPOR III, have been announced by Seres Therapeutics Inc (NASDAQ:MCRB). The drug is meant to......
(read more)March 17 - News, Stock Analysis - Comments
Target Corporation (NYSE:TGT) operates general merchandise stores in the United States and Canada. Target is a dividend champion, which has paid dividends......
(read more)March 17 - Dividend Stocks, News, Stock Analysis - Comments
Here’s a look at some of the week’s biggest movers in biotech, what’s moving them, and where we expect things to go early next week and beyond.......
(read more)March 17 - Market Movers, News, Stock Analysis - Comments
The Melody Transcatheter Pulmonary Valve that has been developed by Medtronic PLC. Ordinary Shares (NYSE:MDT) has been approved by the U.S. Food and Drug......
(read more)March 17 - News, Stock Analysis - Comments
Reports indicate that there are a number of plaintiffs filing lawsuits against Merck & Co., Inc. (NYSE:MRK) claiming that its shingles vaccine, Zostavax......
(read more)March 16 - News, Stock Analysis - Comments
After recently getting the approval of the U.S. Food and Drug Administration, Novartis AG (ADR) (NYSE:NVS) has announced that a flexible pricing system......
(read more)March 16 - News, Stock Analysis - Comments
Lynparza, an ovarian cancer treatment developed by AstraZeneca PLC (ADR) (NYSE:AZN) has demonstrated its ability to slow down disease progression. AstraZeneca......
(read more)March 16 - News, Stock Analysis - Comments
The head of technical analysis at Oppenheimer (1), Ari Wald, is bullish on Skyworks Solutions Inc (NASDAQ:SWKS). He cites that technology is currently......
(read more)March 16 - News, Stock Analysis, Tech - Comments
After struggling throughout the latter half of 2016 with various development and regulatory pressures, Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) has......
(read more)March 16 - News, Stock Analysis - Comments
By Pablo Erbar Cellular Biomedicine Group Inc (NASDAQ:CBMG) is a developer of proprietary cell therapies for the treatment of cancer and other degenerative......
(read more)March 16 - News, Stock Analysis - Comments
By Pablo Erbar Last month Vuzix Corporation (NASDAQ:VUZI) disclosed plans to build a pair of custom smart glasses for Toshiba Client Solutions Co. Ltd......
(read more)March 16 - News, Stock Analysis, Tech - Comments
The world’s largest and most-valued semiconductor chip maker, Intel Corporation (NASDAQ:INTC), is about to buy Israeli driverless car technology company......
(read more)March 15 - News, Stock Analysis, Tech - Comments
In the Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) public offering, common shares totaling 22,300,000 will be offered at $6.75 a share. The biopharmaceutical......
(read more)March 15 - News, Stock Analysis - Comments
It’s been a big week for PARP inhibitors. AstraZeneca PLC (ADR) (NYSE:AZN) just put out data from a phase 3 investigation of its lead PARP asset Lynparza......
(read more)March 15 - News, Stock Analysis - Comments
I have owned shares of the largest Canadian Banks as a long-term investment for over four years now. I initiated a position in those five banks in early......
(read more)March 15 - Dividend Stocks, News, Stock Analysis - Comments
In its efforts to contribute to a generation that is tobacco-free, CVS Health Corp (NYSE:CVS) has devoted $50 million for a five-year program. The drug......
(read more)March 14 - News, Stock Analysis - Comments
AstraZeneca plc (ADR) (NYSE:AZN) is reconsidering some of its rejected drugs, as they could possess potential in curing a disease they were not initially......
(read more)March 14 - News, Stock Analysis - Comments
It’s been a busy quarter in the biotechnology space, but it’s not over yet. This month promises to bring with it a flurry of end of quarter catalysts......
(read more)March 14 - News, Stock Analysis - Comments
